Trial Profile
A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naive Subjects With Chronic HCV Infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Nov 2019
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary) ; Sofosbuvir/velpatasvir
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms POLARIS-2
- Sponsors Gilead Sciences
- 01 Oct 2018 Results of a pooled analysis assessing patients reported outcomes from 11 studies, published in the Value in Health.
- 05 Dec 2017 Results of resistance analysis in HCV infected patients Genotype 1-6 from phase III studies (ASTRAL-1, ASTRAL-2, ASTRAL-3, ASTRAL-5 and POLARIS-2, POLARIS-3; n=1778) published in the Journal of Hepatology
- 27 Nov 2017 Results assessing patient-reported outcomes from POLARIS 2 and 3 (n=1160) published in the Alimentary Pharmacology and Therapeutics